Device Trial Radar · NCT07668193
GlaukomAI: Clinical Validation of an AI System for Early Glaucoma Screening
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Nov 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Fondazione G.B. Bietti, IRCCSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Glaucoma is one of the leading causes of irreversible blindness worldwide. Early diagnosis is crucial to prevent vision loss, but current diagnostic pathways require multiple specialist visits and tests, leading to long waiting times and delayed diagnosis. This study aims to evaluate the accuracy of GlaukomAI, an artificial intelligence (AI)-based software that analyzes fundus photographs of the eye to detect glaucoma at an early stage. The study is conducted at IRCCS Fondazione G. B. Bietti (Rome, Italy) and is structured in two phases: * Phase 1 enrolls 200 participants (100 with diagnosed glaucoma and 100 healthy controls) to assess how accurately GlaukomAI can distinguish between glaucoma and healthy eyes, compared to the judgment of a panel of three expert glaucoma specialists. * Phase 2 enrolls 1,000 consecutive outpatients to evaluate whether GlaukomAI can correctly identify patients who need referral to a glaucoma specialist, and to compare its performance with that of non-specialist ophthalmologists. Participants undergo a single study visit including standard ophthalmic examinations (visual acuity, eye pressure measurement, visual field test, OCT, and fundus photography). No investigational drugs or invasive procedures are involved. The results of this study will provide evidence to support the integration of AI-based tools into routine glaucoma screening pathways, with the goal of reducing diagnostic delays and improving access to care.
Conditions
- Glaucoma
Interventions
GlaukomAI (Sens-vue GlaukomAI)Device
GlaukomAI is an AI-based diagnostic software (Sens-vue ApS) that analyzes standard fundus photographs to detect glaucomatous changes. The system uses deep learning with Convolutional Neural Network and Transformer architecture to evaluate key glaucoma biomarkers, including neuroretinal rim appearance in the inferior and superior sectors. It accepts standard fundus images acquired with conventional fundus cameras or portable devices and provides a diagnostic classification (Referable Glaucoma / Non-Referable Glaucoma) within 2-8 seconds per image. The system is not CE-marked. Fundus images are acquired using a widefield TrueColor Confocal fundus imaging system (iCare DRS Plus), pseudonymized, and uploaded to the GlaukomAI secure platform by an operator blinded to the clinical diagnosis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnostic Accuracy of GlaukomAI - Sensitivity and SpecificityTime frame: At enrollment visit (single visit, or two consecutive visits within 1 week)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.